Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention

References

• Newman P, Derbes R, Aster R. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest.83, 1778–1781 (1989).
   PubMed Web of Science ®Google Scholar
• Kabir-Salmani M, Fukuda MN, Kanai-Azuma M et al. The membrane-spanning domain of CD98 heavy chain promotes aVb3 integrin signals in human extravillous throphoblasts. Mol. Endocrinol.22, 707–715 (2008).
   PubMedGoogle Scholar
• Kjeldsen-Kragh J, Killie MK, Tomter G et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood110, 833–839 (2007).
   PubMed Web of Science ®Google Scholar
• Kaplan C, Daffos F, Forestier F, Morel MC, Chesnel N, Tchernia G. Current trends in neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Platelet Immunology: Fundamental and Clinical Aspects. Kaplan-Gouet C, Schlegel N, Salmon Ch, McGregor J (Eds). Colloque INSERM/John Libbey Eurotext Ltd, Paris, France 267–278 (1991).
   Google Scholar
• Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust. NZ J. Obstet. Gynaecol.41, 45–55 (2001).
   PubMed Web of Science ®Google Scholar
• Mueller-Eckhardt C, Grubert A, Weisheit M et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet333, 363–366 (1989).
   Google Scholar
• Muller JY, Reznikoff-Etievant MF, Patereau C, Dangu C, Chesnel N. Neonatal alloimmune thrombopenia. Clinical and biological study of 84 cases. Presse Med.14, 83–86 (1985).
   PubMed Web of Science ®Google Scholar
• Ahlen MT, Husebekk A, Killie MK, Skogen B, Stuge TB. T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells. Blood113, 3838–3844 (2009).
   PubMed Web of Science ®Google Scholar
• L’Abbe D, Tremblay L, Filion M et al. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Hum. Immunol.34, 107–114 (1992).
   PubMed Web of Science ®Google Scholar
• Williamson LM, Hackett G, Rennie J et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood92, 2280–2287 (1998).
   PubMed Web of Science ®Google Scholar
• Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica93, 870–877 (2008).
   PubMed Web of Science ®Google Scholar
• Ahlen MT, Killie MK, Husebekk A, Kjeldsen-Kragh J, Olsson ML, Skogen B. The development of severe anti-HPA 1a-related neonatal alloimmune thrombocytopenia is influenced by the maternal ABO type. Blood110, 623–623 (2007).
   Google Scholar
• Bussel JB, Zacharoulis S, Kramer K et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr. Blood Cancer45, 176–183 (2005).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev.22, 33–52 (2008).
   PubMed Web of Science ®Google Scholar
• Tiller H, Killie MK, Skogen B, Oian P, Husebekk A. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG116, 594–598 (2009).
   PubMed Web of Science ®Google Scholar
• Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N. Engl. J. Med.20, 1463–1466 (1993).
   Google Scholar
• Turner ML, Bessos H, Fagge T et al. Prospective epidemiologic study of the outcome and cost–effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion45, 1945–1956 (2005).
   PubMed Web of Science ®Google Scholar
• Uhrynowska M, Niznikowska-Marks M, Zupanska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur. J. Haematol.64, 42–46 (2000).
   PubMed Web of Science ®Google Scholar
• Bassler D, Greinacher A, Okascharoen C et al. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion48, 92–98 (2008).
   PubMed Web of Science ®Google Scholar
• Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst. Rev. CD004226 (2005).
   PubMedGoogle Scholar
• Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost–effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG114, 588–595 (2007).
   Google Scholar
• Gruel Y, Boizard B, Daffos F, Forestier F, Caen J, Wautier JL. Determination of platelet antigens and glycoproteins in the human fetus. Blood68, 488–492 (1986).
   PubMed Web of Science ®Google Scholar
• Giovangrandi Y, Daffos F, Kaplan C, Forestier F, Mac AJ, Moirot M. Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia. Lancet336, 310 (1990).
   PubMedGoogle Scholar
• Murphy MF, Metcalfe P, Waters AH, Ord J, Hambley H, Nicolaides K. Antenatal management of severe feto–maternal alloimmune thrombocytopenia: HLA incompatibility may affect responses to fetal platelet transfusions. Blood81, 2174–2179 (1993).
   PubMed Web of Science ®Google Scholar
• Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia. Vox Sang.85, 326–327 (2003).
   PubMed Web of Science ®Google Scholar
• Jocelyn LJ, Casiro OG. Neurodevelopmental outcome of term infants with intraventricular hemorrhage. Am. J. Dis. Child.146, 194–197 (1992).
   PubMedGoogle Scholar
• Mao C, Guo J, Chituwo BM. Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants. J. Trop. Pediatr.45, 237–240 (1999).
   PubMed Web of Science ®Google Scholar
• Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang. 84, 318–325 (2003).
   Google Scholar
• Dale ST, Coleman LT. Neonatal alloimmune thrombocytopenia: antenatal and postnatal imaging findings in the pediatric brain. AJNR Am. J. Neuroradiol.23, 1457–1465 (2002).
   PubMed Web of Science ®Google Scholar
• Ghevaert C, Campbell K, Walton J et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion47, 901–910 (2007).
   PubMed Web of Science ®Google Scholar
• Bonacossa IA, Jocelyn LJ. Alloimmune thrombocytopenia of the newborn: neurodevelopmental sequelae. Am. J. Perinatol.13, 211–215 (1996).
   PubMed Web of Science ®Google Scholar
• Cota F, Zuppa AA, Luciano R et al. A severe case of intracranial hemorrhage due to alloimmune thrombocytopenia. J. Matern. Fetal. Neonatal. Med.21, 852–854 (2008).
   PubMed Web of Science ®Google Scholar
• Govaert P, Bridger J, Wigglesworth J. Nature of the brain lesion in fetal allo-immune thrombocytopenia. Dev. Med. Child. Neurol.37, 485–495 (1995).
   PubMed Web of Science ®Google Scholar
• Herman J, Jumbelic M, Ancona R, Kickler T. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am. J. Pediatr. Hematol. Oncol.8, 312–317 (1986).
   Google Scholar
• Lester RB 3rd, Sty J. Prenatal diagnosis of cystic CNS lesions in neonatal isoimmune thrombocytopenia. J. Ultrasound Med.6, 479–481 (1987).
   PubMed Web of Science ®Google Scholar
• Morales WJ, Stroup M. Intracranial hemorrhage in utero due to isoimmune neonatal thrombocytopenia. Obstet. Gynecol.65, 20S–21S (1985).
   Google Scholar
• Póvoa AM, Ramalho C, Machado AP, Matias A, Montenegro N. Congenital posthemorrhagic hydrocephalus: a case of fetomaternal alloimmune thrombocytopenia. Fetal Diagn. Ther.22, 321–324 (2007).
   PubMed Web of Science ®Google Scholar
• Kaplan C, Daffos F, Forestier F et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood72, 340–343 (1988).
   PubMed Web of Science ®Google Scholar
• Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N. Engl. J. Med.337, 22–26 (1997).
   PubMed Web of Science ®Google Scholar
• Khouzami AN, Kickler TS, Callan NA, Shumway JB, Perlman EJ, Blakemore KJ. Devastating sequelae of alloimmune thrombocytopenia: an entity that deserves more attention. J. Matern. Fetal Med.5, 137–141 (1996).
   PubMedGoogle Scholar
• Kroll H, Kiefel V, Giers G et al. Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia. Transfus. Med.4, 293–296 (1994).
   PubMed Web of Science ®Google Scholar
• Lindemann R, Svenningsen L, Kjeldsen-Kragh J, Stiris T, Killie M, Husebekk A. Three special cases of pregnancy outcome to reflect about. Tidsskr. Nor. Laegeforen.9, 2244–2246 (2004).
   Google Scholar
• Groves AM, Clough V, Stevens R. Neonatal alloimmune thrombocytopenia may be less severe in a subsequent pregnancy. Pediatr. Hematol. Oncol.20, 393–398 (2003).
   PubMed Web of Science ®Google Scholar
• Goyenaga M, Fromont P, Muller JY, Valentin N. A HPA-1a negative woman immunized against HPA-1a antigen by platelet transfusion gave birth to a healthy HPA-1a positive child after disparition of the anti-HPA 1a at the end of pregnancy. A case report. Presented at: 7th European Symposium on platelet, granulocyte and red cell immunology. Lago Maggiore, Italy, 11–14 April 2002.
   Google Scholar
• Birchall JE, Murphy MF, Kaplan C, Kroll H; European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto–maternal alloimmune thrombocytopenia. Br. J. Haematol.122, 275–288 (2003).
   PubMed Web of Science ®Google Scholar
• Gaddipati S, Berkowitz RL, Lembet AA, Lapinski R, McFarland JG, Bussel JB. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am. J. Obstet. Gynecol.185, 976–980 (2001).
   PubMed Web of Science ®Google Scholar
• Silver RM, Porter TF, Branch DW, Esplin MS, Scott JR. Neonatal alloimmune thrombocytopenia: antenatal management. Am. J. Obstet. Gynecol.182, 1233–1238 (2000).
   PubMed Web of Science ®Google Scholar
• Ghevaert C, Campbell K, Stafford P et al. HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia. Transfusion47, 1296–1305 (2007).
   PubMed Web of Science ®Google Scholar
• Bertrand G, Martageix C, Jallu V, Vitry F, Kaplan C. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J. Thromb. Haemost.4, 628–637 (2006).
   PubMed Web of Science ®Google Scholar
• Jægtvik S, Husebekk A, Aune B, Øian P, Dahl LB, Skogen B. Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG107, 691–694 (2000).
   PubMedGoogle Scholar
• Wu S, Maslanka K, Gorski J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J. Immunol.158, 3221–3226 (1997).
   PubMed Web of Science ®Google Scholar
• Maslanka K, Yassai M, Gorski J. Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J. Clin. Invest.98, 1802–1808 (1996).
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Murphy MF, Soothill PW, Lucas GF, Elson CJ, Kumpel BM. Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism. Clin. Exp. Immunol.142, 92–102 (2005).
   PubMed Web of Science ®Google Scholar
• Sukati H, Bessos H, Barker RN, Urbaniak SJ. Characterization of the alloreactive helper T-cell response to the platelet membrane glycoprotein IIIa (integrin-b3) in human platelet antigen-1a alloimmunized human platelet antigen-1b1b women. Transfusion45, 1165–1177 (2005).
   PubMed Web of Science ®Google Scholar
• Anani Sarab G, Moss M, Barker RN, Urbaniak SJ. Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3*0101-positive antigen-presenting cells. Blood114, 1954–1957 (2009).
   PubMed Web of Science ®Google Scholar
• Rayment R, Kooij TW, Zhang W et al. Evidence for the specificity for platelet HPA-1a alloepitope and the presenting HLA-DR52a of diverse antigen-specific helper T cell clones from alloimmunized mothers. J. Immunol.183, 677–686 (2009).
   PubMed Web of Science ®Google Scholar
• Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat. Rev. Drug Discov.8, 645–660 (2009).
   PubMed Web of Science ®Google Scholar
• Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull. World Health Organ.86, 317–319 (2008).
   PubMed Web of Science ®Google Scholar
• Murphy MF, Williamson LM. Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK national screening committee. Br. J. Haematol.111, 726–732 (2000).
   PubMed Web of Science ®Google Scholar
• Chaoying M, Junwu G, Chituwo BM. Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants. J. Trop. Pediatr.45, 237–240 (1999).
   PubMed Web of Science ®Google Scholar
• Tiller H, Chen P, Skogen B et al. Administration of anti-platelet antibodies prevents the anti-platelet immune response and bleeding complications of neonatal immune thrombocytopenia in a murine model. Blood114, 97–97 (2009).
   Google Scholar
• Koelewijn JM, de Haas M, Vrijkotte TG, van der Schoot CE, Bonsel GJ. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG116, 1307–1314 (2009).
   PubMed Web of Science ®Google Scholar
• Skogen B, Husebekk A, Killie MK, Kjeldsen-Kragh J. Neonatal alloimmune thrombocytopenia is not what it was. A lesson learned from from a large prospective screening and intervention program. Scand. J. Immunol.70, 531–534 (2009).
   PubMed Web of Science ®Google Scholar